Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Gwenn Hansen Sells 3,690 Shares

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 3,690 shares of the stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $73,246.50. Following the transaction, the insider now owns 55,937 shares in the company, valued at $1,110,349.45. This represents a 6.19 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Nurix Therapeutics Stock Up 1.8 %

NASDAQ:NRIX traded up $0.36 during trading hours on Thursday, reaching $20.01. 695,140 shares of the stock were exchanged, compared to its average volume of 662,076. Nurix Therapeutics, Inc. has a twelve month low of $7.79 and a twelve month high of $29.56. The business has a 50-day moving average of $20.14 and a two-hundred day moving average of $22.40. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of -6.88 and a beta of 2.14.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. On average, research analysts forecast that Nurix Therapeutics, Inc. will post -2.81 EPS for the current fiscal year.

Institutional Investors Weigh In On Nurix Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers grew its stake in shares of Nurix Therapeutics by 13.5% in the fourth quarter. Rhumbline Advisers now owns 103,233 shares of the company’s stock worth $1,945,000 after acquiring an additional 12,315 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in Nurix Therapeutics by 42.7% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company’s stock worth $14,869,000 after purchasing an additional 235,971 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Nurix Therapeutics by 21.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 15,020 shares of the company’s stock worth $283,000 after purchasing an additional 2,632 shares during the period. SG Americas Securities LLC raised its position in Nurix Therapeutics by 31.1% in the 4th quarter. SG Americas Securities LLC now owns 30,086 shares of the company’s stock valued at $567,000 after purchasing an additional 7,141 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in Nurix Therapeutics by 85.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 68,148 shares of the company’s stock valued at $1,531,000 after purchasing an additional 31,352 shares in the last quarter.

Analysts Set New Price Targets

NRIX has been the topic of a number of recent analyst reports. Jefferies Financial Group initiated coverage on Nurix Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $41.00 target price on the stock. Stifel Nicolaus increased their price objective on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday. UBS Group assumed coverage on shares of Nurix Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $35.00 target price for the company. BMO Capital Markets assumed coverage on shares of Nurix Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $35.00 price target on the stock. Finally, Stephens reiterated an “overweight” rating and set a $31.00 price objective on shares of Nurix Therapeutics in a research note on Tuesday, January 21st. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, Nurix Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $30.71.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.